Direct Healthcare Professional Communication

12 April 2019
print version

Systemic and inhaled quinolone and fluoroquinolone antibiotics - risk of disabling, long lasting and potential irreversible side effects and restrictions on use.

Please see attached letter for more information . 


 Direct Healthcare Professional Communication 09.04.2019 (Direct_Healthcare_Professional_Communication_09.04.2019.pdf | 1.19 MB)


Email:, Tel: 01 6763705, Fax: 01 6765850
Learn More To give you the best possible experience, our sites use cookies. Continuing with cookies enabled means you're OK with this. Click Learn More for more information about our cookies, and how to disable them. ×